Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02320253 · ClinicalTrials.gov registry record · NA

REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes

A NA study of Obesity and Type 2 Diabetes Mellitus, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
211
Enrollment target
4
Study locations

NCT02320253: Completed NA study of Obesity and Type 2 Diabetes Mellitus, sponsored by Massachusetts General Hospital.

NCT02320253 is a NA study of Obesity and Type 2 Diabetes Mellitus that has completed, run by Massachusetts General Hospital. The registered enrollment target is 211 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (74% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02320253, a NA study of Obesity and Type 2 Diabetes Mellitus, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
211 participants
Enrollment target
4
Study locations

Study Summary

The goal of this project is to translate the Look AHEAD intensive lifestyle intervention for type 2 diabetes and obesity into usual care at community health centers, comparing an in-person group program (IP), a telephone conference call (TCC) group program, and referral to medical nutrition therapy (MNT), the current standard of care.

Primary Outcome

Percent weight change form baseline; negative values indicate weight loss.

Interventions

  • BEHAVIORAL In Person Group (IP)
  • BEHAVIORAL Telephone Conference Call Group (TCC)
  • BEHAVIORAL Medical Nutrition Therapy (MNT)

Study Locations (4)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Charlestown HealthCare Center - Charlestown
  • Chelsea HealthCare Center - Chelsea
  • Revere HealthCare Center - Revere

Trial Details

FieldValue
Enrollment Target 211 participants
Start Date 2014-11
Est. Completion 2021-07
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT02320253 record still lists

NCT02320253 is an interventional study that assigns participants to a tested intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (74% lower).

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which In Person Group (IP) is the first listed.

NCT02320253 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02320253 about?

NCT02320253 is a clinical study titled "REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes". The goal of this project is to translate the Look AHEAD intensive lifestyle intervention for type 2 diabetes and obesity into usual care at community health centers, comparing an in-person group program (IP), a telephone conference call (TCC) group program, and referral to medical nutrition therapy ...

What is the current status of trial NCT02320253?

This trial is currently completed. It is a NA study. The enrollment target is 211 participants. The study started on 2014-11. Estimated completion is 2021-07.

What conditions does trial NCT02320253 study?

This clinical trial studies the following conditions: Obesity, Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT02320253?

The interventions under investigation include: In Person Group (IP) (BEHAVIORAL), Telephone Conference Call Group (TCC) (BEHAVIORAL), Medical Nutrition Therapy (MNT) (BEHAVIORAL).

Who is sponsoring clinical trial NCT02320253?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02320253 being conducted?

This trial has 4 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02320253's enrollment target sits among peer trials

211 302nd of 1053 higher than 752 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06698796 · 211 participants · Phase 3

    A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

  • NCT04228978 · 212 participants · NA

    Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

  • NCT04725721 · 212 participants · NA

    Testing FIRST in Youth Outpatient Psychotherapy

  • NCT06257576 · 212 participants · Phase 3

    Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02320253, the US trial registry maintained by the National Library of Medicine. NCT02320253 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.